 Grifols MCE: GRF, MCE: GRF.P, NASDAQ: GRFS, a leading global producer of plasma-derived medicines, today concluded more than a year of encouraging results of its AMBAR Alzheimer Management by Albumin Replacement clinical trial with the presentation of new neuroimaging data that show the reduction in the progression of the disease in patients with mild-to-moderate Alzheimers disease. 